RECRUITING

Molecular Analysis for Precision Surgery in Thyroid Cancer Trial

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Ideal surgical extent for differentiated thyroid cancer remains unclear. Routine use of molecular analysis in biopsy-proven thyroid cancer could provide important prognostic information to help guide extent of surgery - thyroid lobectomy versus total thyroidectomy. This is a pilot feasibility study for the use of routine molecular analysis in Bethesda V and VI thyroid cancers, with randomization of the intermediate-molecular risk subgroup to thyroid lobectomy and total thyroidectomy. The investigators hypothesize that patients will 1) agree to preoperative molecular analysis, and 2) 50% of intermediate-risk patients will agree to and follow through with randomization. This will be a pilot study for a future randomized controlled trial (RTC) to compare between the two surgical approaches in intermediate-molecular risk thyroid cancer.

Official Title

Molecular Analysis for Precision Surgery in Thyroid Cancer (MAPS) Trial

Quick Facts

Study Start:2024-07-30
Study Completion:2026-04-08
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06235814

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients aged 18 years or older at the time of enrollment
  2. * English-speaking
  3. * Bethesda V or VI thyroid nodule that are 1-4cm in size
  4. * Bethesda III or IV nodules who underwent previously underwent Thyroseq molecular analysis that returned with intermediate molecular risk disease
  1. * Prior thyroid operation
  2. * Extrathyroidal extension or lymph node metastases seen on ultrasound
  3. * Distant metastatic disease

Contacts and Locations

Study Contact

Young-Ji Seo, MD
CONTACT
310 206-9145
yseo@mednet.ucla.edu
Elena G Hughes
CONTACT
310-794-9220
eghughes@mednet.ucla.edu

Study Locations (Sites)

University of California Los Angeles
Los Angeles, California, 90095
United States

Collaborators and Investigators

Sponsor: University of California, Los Angeles

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-07-30
Study Completion Date2026-04-08

Study Record Updates

Study Start Date2024-07-30
Study Completion Date2026-04-08

Terms related to this study

Keywords Provided by Researchers

  • Radioactive Iodine
  • Fine Needle Aspiration
  • Parathyroid Hormone
  • Thyroid Stimulating Hormone
  • Thyroglobulin

Additional Relevant MeSH Terms

  • Papillary Thyroid Cancer